Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Brainstorm Cell
(NASDAQ:BCLI)
Intraday
$0.5552
0.0232
[4.36%]
After-Hours
$0.5552
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.5552
0.0232
[4.36%]
At close: Apr 26
$0.5552
0
[0.00%]
After Hours: 4:11PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Brainstorm Cell Stock (NASDAQ:BCLI)
Brainstorm Cell Stock (NASDAQ: BCLI)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 17, 2024
Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
Benzinga Newsdesk
-
Apr 17, 2024, 2:54AM
Thursday, April 11, 2024
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
Benzinga Newsdesk
-
Apr 11, 2024, 6:02AM
Wednesday, April 10, 2024
Brainstorm Cell Therapeutics Announced Peer-reviewed Publication Of Phase 3 Biomarker Data In Muscle And Nerve Suggesting That Debamestrocel Or NurOwn May Impact Key Biomarkers In Amyotrophic Lateral Sclerosis That Are Predictive Of Disease Progression
Benzinga Newsdesk
-
Apr 10, 2024, 6:02AM
Tuesday, April 09, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Apr 9, 2024, 8:09AM
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Apr 9, 2024, 6:05AM
Brainstorm Cell Therapeutics Received Written Agreement From FDA, Under Special Protocol Assessment, On Design For Phase 3B Trial Of NurOwn In Amyotrophic Lateral Sclerosis Expected To Start In 2024
Benzinga Newsdesk
-
Apr 9, 2024, 6:02AM
Monday, April 01, 2024
Brainstorm Cell Q4 EPS $(0.11) Beats $(0.15) Estimate
Benzinga Newsdesk
-
Apr 1, 2024, 3:47PM
Brainstorm Cell Therapeutics shares are trading higher. The company reported FY23 financial results.
Benzinga Newsdesk
-
Apr 1, 2024, 1:24PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Apr 1, 2024, 12:31PM
Brainstorm Cell: Q4 Earnings Insights
Benzinga Insights
-
Apr 1, 2024, 10:35AM
BrainStorm Cell Therapeutics Reported FY23 EPS Loss of $(0.40), Cash Balance of $1.45M
Benzinga Newsdesk
-
Apr 1, 2024, 8:08AM
Monday, March 25, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Mar 25, 2024, 5:32PM
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Mar 25, 2024, 2:44PM
Wednesday, March 20, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Mar 20, 2024, 1:31PM
Tuesday, March 05, 2024
Brainstorm Cell Therapeutics Has Been Granted Israeli Patent Number 277447 Titled "Cell-Type Specific Exosomes And Use Thereof (For The Treatment Of Neurodegenerative Diseases)"
Benzinga Newsdesk
-
Mar 5, 2024, 12:17PM
Tuesday, February 27, 2024
Brainstorm Cell Therapeutics Will Present A Poster Outlining The Proposed Design For A Phase 3B Trial Of Nurown In Amyotrophic Lateral Sclerosis At The MDA Clinical And Scientific Conference, On Monday
Benzinga Newsdesk
-
Feb 27, 2024, 6:39AM
Friday, February 23, 2024
Brainstorm Cell Therapeutics Submits Special Protocol Assessment (Spa) Request To Fda For Phase 3B Trial Of Nurown In Amyotrophic Lateral Sclerosis
Benzinga Newsdesk
-
Feb 23, 2024, 6:06AM
Wednesday, February 21, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Feb 21, 2024, 4:31PM
Monday, February 19, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Feb 19, 2024, 8:05AM
Tuesday, February 13, 2024
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society (ORS) 2024 Annual Meeting
Faith Ashmore
-
Sponsored
Tuesday, January 30, 2024
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Jan 30, 2024, 1:18PM
Monday, January 22, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Jan 22, 2024, 4:31PM
Friday, January 12, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Jan 12, 2024, 4:31PM
Wednesday, December 27, 2023
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Dec 27, 2023, 2:11PM
Why Ascent Industries Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Dec 27, 2023, 8:14AM
Tuesday, December 26, 2023
Brainstorm Cell Therapeutics shares are trading higher after the company announced that it was granted patents for Allogeneic Exosome Platform-Product in neurological disorder treatments.
Benzinga Newsdesk
-
Dec 26, 2023, 9:07AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Dec 26, 2023, 8:07AM
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
Benzinga Newsdesk
-
Dec 26, 2023, 7:31AM
Wednesday, December 20, 2023
BrainStorm Issues 2023 Letter To Shareholders; Says Our Focus Remains To Align With The FDA On A Phase 3b Trial Design, As We Acknowledge That This Represents The Most Expedient Pathway To Approval
Benzinga Newsdesk
-
Dec 20, 2023, 9:02AM
Thursday, December 07, 2023
Why BrainStorm Cell Therapeutics Shares Are Falling
Henry Khederian
-
Dec 7, 2023, 2:57PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Dec 7, 2023, 12:31PM
BrainStorm Cell Therapeutics Announces Outcome Of FDA Meeting On NurOwn In ALS
Benzinga Newsdesk
-
Dec 7, 2023, 8:41AM
Wednesday, December 06, 2023
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Dec 6, 2023, 8:06AM
Tuesday, December 05, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Dec 5, 2023, 12:31PM
Tuesday, November 21, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Nov 21, 2023, 12:31PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Nov 21, 2023, 8:06AM
Monday, November 20, 2023
BrainStorm Cell Therapeutics Announces In-Person Meeting With The FDA To Discuss Confirmatory Phase 3 Trial For NurOwn In ALS
Benzinga Newsdesk
-
Nov 20, 2023, 8:12AM
Tuesday, November 14, 2023
Earnings Scheduled For November 14, 2023
Benzinga Insights
-
Nov 14, 2023, 8:23AM
Brainstorm Cell Q3 EPS $(0.03) Beats $(0.14) Estimate
Benzinga Newsdesk
-
Nov 14, 2023, 7:41AM
Brainstorm Cell: Q3 Earnings Insights
Benzinga Insights
-
Nov 14, 2023, 7:10AM
Monday, November 13, 2023
Brainstorm Cell's Earnings: A Preview
Benzinga Insights
-
Nov 13, 2023, 9:00AM
Wednesday, November 01, 2023
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Nov 1, 2023, 8:07AM
Tuesday, October 24, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Oct 24, 2023, 1:31PM
Wednesday, October 18, 2023
BrainStorm Cell Therapeutics To Meet With US FDA To Discuss Development Plan For NurOwn As A Treatment Of ALS; Biologics License Application To Be Withdrawn Without Prejudice
Benzinga Newsdesk
-
Oct 18, 2023, 6:03AM
Tuesday, October 10, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 10, 2023, 1:09PM
Thursday, October 05, 2023
Brainstorm Cell Therapeutics Published U.S. Patent App #20230310507 Today For "Methods And Compositions For Treating Lung Conditions"
Benzinga Newsdesk
-
Oct 5, 2023, 10:42AM
Wednesday, October 04, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Oct 4, 2023, 1:31PM
Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Oct 4, 2023, 12:48PM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Oct 4, 2023, 9:06AM
Why Brooge Energy Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Oct 4, 2023, 8:03AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch